Management of high blood pressure in type 2 diabetes: perindopril/indapamide fixed-dose combination and the ADVANCE trial

Bibliography

• International Diabetes Federation.Diabetes Atlas. 3rd edition. Brussels: International Diabetes Federation, 2006
   Google Scholar
• Haffner SM, Lehto S, Ronnemaa T, Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34
   PubMed Web of Science ®Google Scholar
• Lawes CM, Parag V, Bennett DA, Asia Pacific Cohort Studies Collaboration. Blood glucose and risk of cardiovascular disease in the Asia Pacific region. Diabetes Care 2004;27:2836-42
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-13. Published erratum appears in BMJ 1999;318:29
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes: UKPDS 33. Lancet 1998;352:837-53
   PubMed Web of Science ®Google Scholar
• Holman RR, Paul SK, Bethel A, 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89
   PubMed Web of Science ®Google Scholar
• Adler A, Stratton IM, Neil H, Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes: UKPDS 36. Prospective observational study. BMJ 2000;321:412-19
   PubMed Web of Science ®Google Scholar
• MacMahon S. ADVANCE Management Committee. Study rationale and design of ADVANCE: Action in Diabetes and Vascular disease–Preterax and Diamicron MR Controlled Evaluation. Diabetologia 2001;44:1118-20
   PubMed Web of Science ®Google Scholar
• Collins R, Peto R, MacMahon S, Blood pressure, stroke, and coronary heart disease. Part 2: short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990;335:827-38
   PubMed Web of Science ®Google Scholar
• Blood Pressure Lowering Treatment Trialists Collaboration. Effects of angiotensin converting enzyme inhibitors, calcium antagonists and other blood pressure lowering drugs on mortality and major cardiovascular morbidity. Lancet 2000;356:1955-64
   PubMed Web of Science ®Google Scholar
• Hansson L, Zanchetti A, Carruthers S, Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:1755-62
   PubMed Web of Science ®Google Scholar
• Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-8
   PubMed Web of Science ®Google Scholar
• Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53
   PubMed Web of Science ®Google Scholar
• ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE Trial): a randomised controlled trial. Lancet 2007;370:829-40
   PubMed Web of Science ®Google Scholar
• ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72
   PubMed Web of Science ®Google Scholar
• de Galan BE, Perkovic V, Ninomiya T, ADVANCE Collaborative Group. Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol 2009;20:883-92
   PubMed Web of Science ®Google Scholar
• Zoungas S, de Galan B, Ninomiya T, The combined effects of routine blood pressure lowering and intensive glucose on macrovascular and microvascular outcomes in patients with type 2 diabetes; new results from ADVANCE. Diabetes Care 2009;32:2068-74
   PubMed Web of Science ®Google Scholar
• The ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010;362:1575-85
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Mann JF, Yi Q, Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001;25:421-6
   Google Scholar
• Ninomiya T, Perkovic V, de Galan B, Albuminuria and kidney function independently predict cardiovascular and renal outcomes in Diabetes. J Am Soc Nephrol 2009;20:1813-21
   PubMed Web of Science ®Google Scholar
• Ninomiya T, Zoungas S, de Galan B, The fixed combination of perindopril and indapamide has a greater effect on cardiovascular outcomes in patients with type 2 diabetes and albuminuria. ADVANCE Collaborative group [abstract]. J Hypertens 2009;27(Suppl 4):S179
   Google Scholar
• Mann JFE, Schmieder RE, McQueen M, on behalf of the ONTARGET Study Group. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008;372:547-53
   PubMed Web of Science ®Google Scholar
• Mann JFE, Schmieder RE, Dyal L, on behalf of the TRANSCEND RENAL Collaborative Group. Effect of telmisartan on renal outcomes. A randomized trial. Ann Intern Med 2009;151:1-10
   PubMed Web of Science ®Google Scholar
• Kengne AP, Czernichow S, Huxley R, on behalf of the ADVANCE Collaborative Group. Blood pressure variables and cardiovascular risk. New findings from Advance. Hypertension 2009;54:399-404
   PubMed Web of Science ®Google Scholar
• Strippoli GF, Craig M, Deeks JJ, Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ 2004;329:828-31
   PubMed Web of Science ®Google Scholar
• Brenner BM, Cooper ME, De Zeeuw D, on behalf of the RENAAL Study Group. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Hunsicker LG, Clarke WR, Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60
   PubMed Web of Science ®Google Scholar
• Parving HH, Lehnert H, Brochner-Mortensen J, Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8
   PubMed Web of Science ®Google Scholar
• Mourad J, Waeber B, Zannad F, on behalf of STRATHE Trial Investigators. Comparison of different therapeutic strategies in hypertension: a low dose combination of perindopril/indapamide versus a sequential monotherapy or a stepped care approach. J Hypertens 2004;22:2379-86
   PubMed Web of Science ®Google Scholar
• Mancia G, DeBacker G, Dominiczak A, Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 Guidelines for the management of arterial hypertension. J Hypertens 2007;25:1105-87
   PubMed Web of Science ®Google Scholar
• Mogensen CE, Viberti G, Halimi S, Preterax in Albuminuria Regression (PREMIER) Study Group. Effect of low-dose perindopril/indapamide on albuminuria in diabetes. Preterax in Albuminuria Regression: PREMIER. Hypertension 2003;41:1063-71
   PubMed Web of Science ®Google Scholar
• Dahlof B, Gosse P, Gueret P, ; on behalf of PICXEL Investigators. Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study. J Hypertens 2005;23:2063-70
   PubMed Web of Science ®Google Scholar
• De Luca N, Mallion JM, O'Rourke MF, REASON Project. Regression of left ventricular mass in hypertensive patients treated with perindopril/indapamide as a first-line combination. The REASON echocardiography study. Am J Hypertens 2004;17:660-7
   PubMed Web of Science ®Google Scholar
• Asmar RG, London GM, O'Rourke ME, on behalf of REASON Project Coordinators and Investigators. Improvement in blood pressure, arterial stiffness and wave reflection with a very-low-dose perindopril/indapamide combination in hypertensive patients: a comparison with atenolol. Hypertension 2001;38:922-6
   PubMed Web of Science ®Google Scholar
• Laurent S, Cockcroft J, Van Bortel L, Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006;27:2588-605
   PubMed Web of Science ®Google Scholar
• Ghiadoni L, Stea F, Bruno RM, Central blood pressure, arterial stiffness, and wave reflection: new targets of treatment in essential hypertension. Curr Hypertens Rep 2009;11:190-6
   PubMed Web of Science ®Google Scholar
• Camici PG, Crea F. Coronary microvascular dysfunction. N Engl J Med 2007;356:2324-5
   PubMed Web of Science ®Google Scholar
• Mourad JJ, Hanon O, Deverre JR, Improvement of impaired coronary vasodilator reserve in hypertensive patients by low-dose ACE inhibitor/diuretic therapy: a pilot PET study. J Renin Angiotensin Aldosterone Syst 2003;4:94-5
   PubMed Web of Science ®Google Scholar
• Neglia D, Fommei E, Ghione S, Coronary microvascular dysfunction in hypertensive patients with left ventricular hypertrophy can be reversed by treatment with a combination of Perindopril/indapamide [abstract]. Eur Heart J 2008;29:103
   Google Scholar
• Lerman A, Zeiher AM. Endothelial function: cardiac events. Circulation 2005;111:363-8
   PubMed Web of Science ®Google Scholar
• Ghiadoni L, Kardasz I, Magagna A, Fixed dose combination of perindopril and indapamide improves peripheral vascular function in essential hypertensive patients. Am J Hypertens 2009;22:506-12
   PubMed Web of Science ®Google Scholar
• Mancia G, Laurent S, Agabiti-Rosei E, Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertension 2009;27:2121-58
   PubMed Web of Science ®Google Scholar